医学
舒尼替尼
药理学
瑞戈非尼
基诺美
帕唑帕尼
帕纳替尼
重症监护医学
癌症
肿瘤科
内科学
尼罗替尼
激酶
伊马替尼
结直肠癌
化学
髓系白血病
生物化学
作者
Mauro Viganò,Marta La Milia,Maria Vittoria Grassini,Ana Lleo,Massimo De Giorgio,Stefano Fagiuoli
出处
期刊:Cancers
[MDPI AG]
日期:2023-03-14
卷期号:15 (6): 1766-1766
被引量:2
标识
DOI:10.3390/cancers15061766
摘要
Small molecule protein kinase inhibitors (PKIs) have become an effective strategy for cancer patients. However, hepatotoxicity is a major safety concern of these drugs, since the majority are reported to increase transaminases, and few of them (Idelalisib, Lapatinib, Pazopanib, Pexidartinib, Ponatinib, Regorafenib, Sunitinib) have a boxed label warning. The exact rate of PKI-induced hepatoxicity is not well defined due to the fact that the majority of data arise from pre-registration or registration trials on fairly selected patients, and the post-marketing data are often based only on the most severe described cases, whereas most real practice studies do not include drug-related hepatotoxicity as an end point. Although these side effects are usually reversible by dose adjustment or therapy suspension, or by switching to an alternative PKI, and fatality is uncommon, all patients undergoing PKIs should be carefully pre-evaluated and monitored. The management of this complication requires an individually tailored reappraisal of the risk/benefit ratio, especially in patients who are responding to therapy. This review reports the currently available data on the risk and management of hepatotoxicity of all the approved PKIs.
科研通智能强力驱动
Strongly Powered by AbleSci AI